Co-Authors
This is a "connection" page, showing publications co-authored by RICHARD KELLERMAYER and LINA KARAM.
Connection Strength
1.495
-
Failure Rate of Anti-Tumor Necrosis Factor a Biologics in Very Early Onset Inflammatory Bowel Disease. Inflamm Bowel Dis. 2024 Mar 01; 30(3):510-512.
Score: 0.248
-
NOD2 Polymorphisms May Direct a Crohn Disease Phenotype in Patients With Very Early-Onset Inflammatory Bowel Disease. J Pediatr Gastroenterol Nutr. 2023 12 01; 77(6):748-752.
Score: 0.235
-
A Single-Center Study of Long-Term Effectiveness of Vedolizumab in Anti-TNF Refractory Pediatric Inflammatory Bowel Disease. JPGN Rep. 2023 Feb; 4(1):e276.
Score: 0.228
-
Infliximab Can Be Effective in Pediatric Patients with Ulcerative Colitis and Primary Failure of Adalimumab. Ann Clin Lab Sci. 2022 Sep; 52(5):796-801.
Score: 0.223
-
High Seroconversion Rate Against Severe Acute Respiratory Syndrome Coronavirus 2 in Symptomatic Pediatric Inflammatory Bowel Disease Patients. J Pediatr Gastroenterol Nutr. 2021 09 01; 73(3):363-366.
Score: 0.208
-
Progression to colectomy in the era of biologics: A single center experience with pediatric ulcerative colitis. J Pediatr Surg. 2020 Sep; 55(9):1815-1823.
Score: 0.187
-
Selective lactase deficiency is common in pediatric patients undergoing upper endoscopy. J Mol Biochem. 2018; 7(1):41-47.
Score: 0.166